All Stories

  1. Council of Europe Resolution on the Implementation of Pharmaceutical Care—A Step Forward in Enhancing the Appropriate Use of Medicines and Patient-Centred Care
  2. Scope, content and quality of clinical pharmacy practice guidelines: a systematic review
  3. Examining Quality, Use and Impact of Psychotropic (Use) in older adults with intellectual disabilities (EQUIP): study protocol
  4. Prescriber’s view on anticholinergic deprescribing among older adults with intellectual disability: A qualitative study protocol
  5. Antimicrobial utilization and resistance in Pseudomonas aeruginosa using segmented regression analysis: a comparative study between Serbia and eight European Countries
  6. How to write a successful grant application: guidance provided by the European Society of Clinical Pharmacy
  7. Evidence of Mental Health Support and the Pharmacist
  8. Examining Quality, Use and Impact of Psychotropic (Use) in older adults with intellectual disabilities (EQUIP): study protocol
  9. The adverse effects of long-term exposure to anticholinergics among people with intellectual disabilities: a scoping review
  10. Online and Blended Learning Courses for Healthcare Professionals and Policymakers on Patients’ Perspectives on Medicine: A Project Report
  11. The relationship between antiepileptic drug load and challenging behaviors in older adults with intellectual disability and epilepsy
  12. Provision of clinical pharmacy services during the COVID-19 pandemic: Experiences of pharmacists from 16 European countries
  13. Pharmacists’ involvement in COVID-19 vaccination across Europe: a situational analysis of current practice and policy
  14. The impact of long-term exposure to anticholinergics among people with intellectual disabilities: a scoping review protocol
  15. Antiepileptic drugs, occurrence of seizures and effect of co‐administration of potential seizure threshold‐lowering psychotropic drugs in adults with intellectual disability who have epilepsy
  16. Experiences of the Medication Use Process by People with Intellectual Disabilities. What a Pharmacist Should Know!
  17. Optimising medicines use in older adults with intellectual disability who have epilepsy: challenges and perspectives
  18. Primary Health Care and Community Pharmacy in Ireland: a lot of visions but little progress
  19. Impact of a global leader on pharmaceutical practice and policy around the world
  20. Pharmacy Education; Competency and Beyond
  21. A survey of the European Society of Clinical Pharmacy members’ research involvement, and associated enablers and barriers
  22. Measuring drug burden in older adults with intellectual disabilities: Critical issues for consideration in finding the optimal measure to improve safety of medicines use
  23. Medication burden and frailty in older adults with intellectual disability: An observational cross‐sectional study
  24. Laxative use among older adults with intellectual disability: a cross-sectional observational study
  25. 18 A Review of Interventions to Improve Medication Adherence in Patients with Parkinson’s Disease
  26. Design and Implementation of an Integrated Competency-Focused Pharmacy Programme: A Case Report
  27. Association of Drug Burden Index with grip strength, timed up and go and Barthel index activities of daily living in older adults with intellectual disabilities: an observational cross-sectional study
  28. Prevalence and patterns of antipsychotic use and their associations with mental health and problem behaviours among older adults with intellectual disabilities
  29. 82Secondary Prevention Post-Hip Fracture – Is Treatment Optimised?
  30. 125Use of the Sedative Load Model in Older Adults with Intellectual Disabilities
  31. Medication use and whether it is appropriate in older people with intellectual disability
  32. Medication Use and Health Screening in an Ageing Adult Population With Down Syndrome in Ireland: A Descriptive Study
  33. The use of drugs to suppress excess stomach acid in older people with intellectual disability.
  34. Measurement of the use of high risk drugs in older people with intellectual disabilities.
  35. Prevalence and patterns of anti‐epileptic medication prescribing in the treatment of epilepsy in older adults with intellectual disabilities
  36. A test of a new system for providing some intravenous anticancer drugs
  37. Medication and supplement use in older people with and without intellectual disability: An observational, cross-sectional study
  38. 165Association of Drug Burden Index with Physical Function in Irish Older Adults with Intellectual Disability
  39. 100Potentially Inappropriate Prescribing of Proton Pump Inhibitors – A Qualitative Study
  40. Prevalence, patterns and factors associated with psychotropic use in older adults with intellectual disabilities in Ireland
  41. Analgesic use by ageing and elderly patients with chronic non-malignant pain: a qualitative study
  42. Association of anticholinergic burden with adverse effects in older people with intellectual disabilities: an observational cross-sectional study
  43. 298 ASSOCIATIONS BETWEEN MEDICATION USE AND FALLS AMONG OLDER ADULTS WITH INTELLECTUAL DISABILITY IN IRELAND
  44. A retrospective cohort analysis of hypoglycaemic and cardiovascular agent use in young adults in the Irish primary care setting
  45. Terminology, the importance of defining
  46. Factors associated with polypharmacy and excessive polypharmacy in older people with intellectual disability differ from the general population: a cross-sectional observational nationwide study
  47. General Practitioners and Chronic Non-Malignant Pain Management in Older Patients: A Qualitative Study
  48. Erratum to: Medical care and drug-related problems: Do doctors and pharmacists speak the same language?
  49. The impact of initial antidiabetic agent and use of monitoring agents on prescription costs in newly treated type 2 diabetes: A retrospective cohort analysis
  50. ReCAP: Hospitalizations in Older Adults With Advanced Cancer: The Role of Chemotherapy
  51. Medical care and drug-related problems: Do doctors and pharmacists speak the same language?
  52. Building quality indicators for medication use in people aging with intellectual disabilities and behaviour disorders
  53. Use of cardiovascular medicines in newly treated type 2 diabetes patients: A retrospective cohort study in general practice
  54. The Impact Of Self-Monitoring Of Blood Glucose (Smbg) On Prescription Costs In Newly Treated Type 2 Diabetes Melitus (T2dm): A Retrospective Cohort Analysis
  55. Venlafaxine for neuropathic pain in adults
  56. Hydroxycinnamic acid amide derivatives of polyamines reverse spermine-induced CNS excitation
  57. Initial therapy, persistence and regimen change in a cohort of newly treated type 2 diabetes patients
  58. Pharmacists’ medicines-related interventions for people with intellectual disabilities: a narrative review
  59. Sedative Load and Frailty Among Community-Dwelling Population Aged ≥65 Years
  60. Treatment-related toxicities in older adults with head and neck cancer: A population-based analysis
  61. Case study: hidden complexity of medicines use: information provided by a person with intellectual disability and diabetes to a pharmacist
  62. Treatment complications and survival in advanced laryngeal cancer: A population-based analysis
  63. Concurrent Use of Drugs and Supplements in a Community-Dwelling Population Aged 50 Years or More: Potential Benefits and Risks
  64. Potential for alcohol and drug interactions in older adults: evidence from the Irish longitudinal study on ageing
  65. Oral Hypoglycaemic Medicine (OHM) Initiation in Newly Treated Type 2 Diabetes Mellitus (T2DM) in Ireland: An Analysis of Treatment Intensification and Switching Patterns
  66. Persistence Patterns with Oral Hypoglycaemic Medicines (OHM) in Newly Treated Irish Patients with Type 2 Diabetes Mellitus (T2DM)
  67. Food supplement use in the community dwelling population aged 50 and over in the Republic of Ireland
  68. Identification of risks associated with the prescribing and dispensing of oral anticancer medicines in Ireland
  69. Costs and trends in pancreatic cancer treatment
  70. Provision of pharmaceutical care by community pharmacists: a comparison across Europe
  71. Authors' response
  72. Over-the-counter cough medicines in children: neither safe or efficacious?
  73. The pre-ischaemic neuroprotective effects of the polyamine analogues BU43b and BU36b in permanent and transient focal cerebral ischaemia models in mice
  74. The pre-ischaemic neuroprotective effects of N1-dansyl-spermine in a transient focal cerebral ischaemia model in mice
  75. The pre-ischaemic neuroprotective effect of a novel polyamine antagonist, N1-dansyl-spermine in a permanent focal cerebral ischaemia model in mice
  76. Drug—Drug Interactions in the Elderly
  77. Improving the Well-Being of Elderly Patients via Community Pharmacy-Based Provision of Pharmaceutical Care
  78. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro.
  79. Molecular genetic approaches to identification, epidemiology and taxonomy of non-albicans Candida species
  80. Oral Candida in HIV Infection and AIDS: New Perspectives/New Approaches
  81. Evaluation of Dandelion for Diuretic Activity and Variation in Potassium Content
  82. Reduced azole susceptibility of oral isolates of Candida albicans from HIV-positive patients and a derivative exhibiting colony morphology variation
  83. Impact of a Nationwide Limited Prescribing List: Preliminary Findings
  84. A SURVEY OF DRUG AND THERAPEUTICS COMMITTEES OPERATING IN IRELAND
  85. Comparison of bioassay methods for the estimation of wound-released prostaglandin-like activity
  86. Effect of Topical Antisepsis Agents on the Release of Prostaglandin-Like Activity from Skin Wounds in Guinea Pigs and Rabbits
  87. A critical evaluation of the use of a cascade superfusion technique for the detection and estimation of biological activity